BIOCYTOGEN-B (02315) surged more than 10% in Hong Kong trading, with shares up 10.39% to HK$57.9 as of the time of writing, on a turnover of HK$80.28 million.

This follows the company's announcement last month that it had entered into a global strategic collaboration agreement with Whitehawk Therapeutics, Inc., covering multiple bispecific antibody-drug conjugate (BsADC) research projects. The two parties will jointly advance a diversified pipeline of next-generation therapeutic products. Notably, it took only about four months from the formal initiation of the cooperation to the signing of the agreement.

Shenwan Hongyuan noted that the company's model animal and preclinical CRO businesses have maintained strong growth momentum for years and have established deep and close partnerships with globally leading innovative drug companies. With high barriers to entry combined with industry tailwinds, its market share is expected to continue rising.

Additionally, the AI+RenMice platform antibody business is accelerating its value realization, with the platform's value and R&D conversion gradually becoming more apparent.